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SUMMARY 
Our work suggests that the Leonhard classification system holds much pron.ise as a framework for 
future nosological development. One might speculate along biochemical lines that the no'isystematic 
subpopulation of schizophrenics may suffer from altered dopamine ^-hydroxylase activity which results 
in an excess of dopamine, Thi* would ex. )Iaiu why this class responds so well to dopamine rtccptor 
blocking agent* when other patient:, do not. 
One might also speculate tint we are dealing with a number of diseases—each with different courses 
and progressing to different end states, but all with common pattern during the acute stage, eg., 
increased dopamine levels or receptor sensitivity levels. This is probably why the acute stage can usually 
be controlled by the administration of a dopamine receptor blocking agent. 
A fuither speculation concerns the catatonic pa'ient- who had begun to respond to psychosocial 
and milieu treatment prior to the introduction of neuroleptics. This particular group of patients do not 
seem to benefit from prophylactic treatment with neuroleptics. If, by activating a patient, catecholamines 
are released, it is hypolhrsized that the Catatonics are a completely separate subpopulation—not just 
clinically—but also biorhemica'ly. 
Completely different types of drues may be helpful for the different schizophrenic subpopulation*. 
Amorg the various substances, propranolol should be considered. Obviously, this drug will not be 
effective in all schizophrenics; but there arc certain types of patients who respond to )3-blockfrs. There 
is also increasing evidence (hit clo'idine (which stimulates alpha-adrenergic receptors) may also have an 
effect on certain schizophrenics The most recent findings is that cholecystokinin—thought for Some time 
to be an exclusively peripheral substance—appears to be present in the brain and available in the form 
of cerulotide, a neuropeptide which is a dopamine agonist. Phis susbtance, also, seems to be effective in 
the treatment of certain schizophrenics. 
Chronic schizophrenia requires re-evaluation and it s'lould be recognized that different drugs are 
effective in different types of patients. There is renewed interest in the various schizophrenic conditions 
and their end states. We must hope that the pharmocologists, provided with sufficient information, 
will search for new drugs with differentiated activities that will meaningfully influence the end states ot 
•chizophrcnic disorders and/or prevent their development. 
That at least one person in 150 is 
affected by schizophrenia is a familiar 
statistics. Less well known is the fact that 
15% of those so di.igr.osed become chro-
nically hospitalized —a percentage more 
or less applicable everywhere in the world. 
Another often unrecognized fact is that 
only 50% of the schizophrenic population 
benefit defini'ely from long-term neuro-
leptic treatment. While a considerably 
higher proportion may, at one time or 
another, respond favorably to neurolep-
tics, only 50% appear to receive definite 
benefit from the administiation of neuro-
leptics on a prophylactic basis. 
Neuroleptics are the pnmary mode 
of treatment for schizophrenia today. 
However, it must be recognized that 
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neuroleptic therapy cannot prevent the 
development of the various end states of 
schizophrenia, although it can modify the 
course of the illness and control an acute 
episode or an exacerbation. Furthermore, 
it must also be remembered that the use 
of neuroleptics is not without its risks. 
As with any potent treatment, there is a 
price to pay for the therapeutic benefits. 
Long-term administration of neuroleptics 
can have serious adverse side-effects. 
One can appreciate the benefits of neuro-
leptics, but it is important to keep in 
mind that a patient treated with these 
drugs on a long-term basis may exhibit 
certain neurological changes, e.g., tardive 
dyskinesia. Given that only 50% of 
schizophrenics benefit from long-term 
treatment, this potential risk must be of 
concern to all treating physicians. 
THE LEONHARD CLASSIFICATION 
Traditional psychiatric thought on 
chronic schizophrenia is based on princi-
ples elaborated by Kraepelin (1896) who, 
with considerations to Kahlbaum's (1876) 
contributions, introduced the time com-
ponent to psychiatry, i.e., that the 
understanding of the course of an illness 
is essential for proper diagnosis. A second 
principle was introduced by Bleuler 
(1950) who described the immediate 
picture of the disease by a careful elabo-
ration of its psychopathological symptoms. 
Wernicke (1906), a contemporary of 
Kraepelin found that diagnosis was especi-
ally difficult in the acute stage of a 
psychiatric illness and recognized that, 
almost regardless of what happens during 
schizophrenia's course, the illness finally 
crystallizes into some type of stable end 
state. It may be five or six years after an 
acute episode has subsided before an 
accurate psychiatric diagnosis can be 
made. This, therefore, shifted the empha-
sis from the acute to the chronic end state 
of the illness. 
Leonhard, a disciple of Wernicke 
and Kleist, continued to emphasize the 
importance of end states (Leonhard, 
1979). He added a third component to 
the concept: the polarity of the illness. 
Like affective psychoses, the schizoph-
renias for Leonhard encompass both 
bipolar and unipolar illnesses. The bipo-
lar illnesses are called nonsystematic 
schizophrenias. They are characterized 
by their intermittent periodicity, their 
partial resemblance to manic-depressive 
disorder and their relatively good prog-
nosis. The unipolar schizophrenic illnesses 
are labelled systematic. Systematic schi-
zophrenias have a downhill course greatly 
resembling that of the organic dementias, 
except that they feature intermissions that 
never quite reach full remission. 
Further, within these two classes 
(systematic and nonsystematic) small 
subpopulations can be discerned by consi-
dering the three crucial components of 
psychiatric diagnosis: psychopathological 
symptoms, behavior and performance. 
These three components are not always 
uniformly impaired. Some patients may 
exhibit very severe psychopathological 
symptoms but have a virtually intact 
performance. Others may have badly 
impaired performance but manifest mini-
mal psychopathology. 
There is, for example, one type of 
paraphrenia (phonemic) in which perfor-
mance remains virtually intact despite 
the fact that patien t is almost permanently 
under the influence of auditory hallucina-
tions- There are hebephrenic patients 
who are almost totally autistic but, with 
prompting and in the right kind of 
environment, may perform exceptionally 
well on routine tasks. Within the 
catatonias, the most severe form of 
schizophrenia, there is a subtype, the 
parakinetic, which displays relatively 
good performance. 
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of these dissociations in the end-states 
and employed them in his conceptualiza-
tion of the schizophrenias. He identified 
three subgroups within the nonsystematic 
class:affect-laden paraphrenia, cataphasia 
and periodic catatonia. He also described 
three sub-groups within the systematic 
class: paraphrenias, hebephrenias and 
catatonias. Finally, Leonhard subdivided 
the paraphrenias into six subtypes, the 
hebephrenias into four and catatonias 
into another six. 
Leonhard conceives the schizophre-
nias as dissocations among the perceptual 
(cognitive), emotional (affective) and 
motor (adaptive) systems. An acute 
episode is characterized by a dissociation 
among these systems leading to a "step-
backwards" in one of the systems. 
Although the term "regression" has been 
contaminated by its use m psychodyna-
mics and in many other contexts, what 
one sees in all these different schizoph-
renic subtypes are different dosages of 
regression in the cognitive, affective or 
adaptive system. 
LEONHARD SUBTYPES AND 
RESPONSIVENESS TO DURGS 
Questions are frequently raised con-
cerning the generality and clinical 
relevance of the Leonhard classification 
system. Wilson and Ban (1983) compared 
two distinct populations which have been 
so classified: 664 patients classined by 
Leonhard (1936) prior to the psychophar-
macological era and 900 patients classi-
fied by Astrup (1979) after the advent 
of psychotropic drugs. A very high 
correlation was obtained between the two 
cohorts: the distribution and rank order 
of the Leonhardian subtypes had not 
changed from the pre-to the post-psycho-
pharmalogical era. 
Also of major importance was the 
work by Hamilton (1962) which demons-
trated dearly that responsiveness to 
different psychotropic drugs varied among 
the different schizophrenic subtyes, He 
was able to demonstrate quite convin-
cingly that 95% of the nonsystematic 
schizophrenics showed moderate to 
marked therapeutic responsiveness to 
neuroleptics. In contrast, a much lower 
percentage of systematic schizophrenics 
reached similar levels of responsiveness to 
neuroleptics. 
Fish also brought to attention that, 
in the most responsive treatment group 
of systematic schizophrenics—the para-
phrenics—therapeutic responsiveness in 
the chronic phase of treatment was less 
than 50%. During the same phase catato-
nics proved virtually unresponsive to 
neuroleptics. Responsiveness here refers 
to maintenance and prophylaxis—not 
acute treatment. Maintenance refers to 
treatment of the patient up to the 
expected end of the acute episode and 
prophylaxis refers to treatment beyond 
that time, i.e.. the prevention of a further 
episode. 
Kelwala and Ban (1981a) described 
a patient who had been diagnosed as 
suffering from febrile catatonia. When 
the patient became feverish, he developed 
delusional ideas, waxy flexibility and 
mutism. He was initially treated with 
haloperidol and later chlorpromazine 
was added—neither with any appreciable 
effect even when the dosage was increased. 
It was decided to reduce his medication 
by discontinuing the chlorpromazine and 
lowering the dosage of the haloperidol. 
As a result the patient improved suffi-
ciently enough to go home for a week. 
There was further improvement at home 
and deterioration upon return to hospital. 
At this point, it was determined that he was 
not taking his medication while at home. 
Since patient seems to fair better without 
drugs, treatment with neuroleptics was 
discontinued altogether. Discontinuation 
of medication was followed by remission SCHIZOPHRENIA: PSYCHOPHARMACOLOGICAL APPROACH  325 
of psychopathological symptoms. It was 
concluded that this patient not only had 
a poor response to neuroleptics; but that 
he may have had a negative response. 
Two other examples involved patients 
who were classified in Lconhard'ssystem as 
shallow hebephrenics (Kelwala and Ban, 
1981b). Their prevailing characteristics 
were flatness of affect, lack of interest and 
total lack of spontaneity. Both were 
admitted to hospital because they expe-
rienced sudden, episodic, hallucinatory 
excitements during which they would 
strike someone or otherwise create a 
disturbance. One patient was treated 
with thiothixene, the other with halope-
ridol. However, when their medications 
were discontinued, no changes were 
observed in their behavior (i.e., their 
episodic outbursts remained at about the 
same frequency whether given neuroleptics 
or not). Although there are indications 
that this particular schizcphrenic subtype 
might be responsive to carbamazepine, in 
these patients carbamazepine remained 
ineffective. There is, therefore, a second 
chronic schizophrenic subtype which 
responds only minimally to neuroleptics 
and consequently does not necessarily 
benefit fiom prophylactic treatment with 
these drugs. 
REGENT WORK 
We are currently carrying out work 
in relation to Leonhard's classification. 
Preliminary data show that not only is 
there different responsiveness to neuro-
leptics among the schizophrenic subpopu-
lations but that these differences may be 
intuitively perceived by psychiatrists who 
prescribe different dosages of neuroleptics 
for what turn out to be specific Leonhard 
subtype. It appears that the nonsyste-
matic class receive significantly higher 
dosages than the systematic class. This is 
important because the nonsystematic class 
seems to be a genetically distinct schizo-
phrenic subpopulation with a relatively 
good prognosis. Among the systematic 
schizophrenics, it was found that the 
paraphrenics were receiving significantly 
higher neuroleptic dosages than the 
hebephrenics and catatonics. This may 
be because neither of the latter two 
subgroups exhibit much response to 
neuroleptic; in chronic treatment. 
Another interesting observation is that 
tardive dyskinesia seems to occur three 
times more frequently in the chronic dis-
organized population, i.e., those patients 
usually falling into the hebephrenic and 
catatonic subgroups, than in the para-
phrenic subgroup Tardive dyskinesia 
was rarely found among nonsystematic 
schizophrenics. It is worth considering 
whether tardive dyskinesia only manifests 
itself is those subgroups which do not 
benefit from prophylactic treatment with 
neuroleptics and which should not have 
been placed on maintenance or prophy-
lactic therapy in the first place. 
Also of interest were the data that 
emerged in relation to lithium. As we 
have been working with chronic patients, 
everything possible including lithium, had 
been tried in order to help them. 
Although we expected little from this 
treatment, it was found that, among 
patients on combined lithium-neuroleptic 
therapy, nine out of 10 nonsystematic 
schizophrenics (mainly affect-laden para-
phrenics) showed a favorable therapeutic 
response and none developed a toxic 
confusional state. In contrast, a conside-
rable proportion of systematic schizo-
phrenics developed a toxic confusional 
state to the combination (Prakash et al., 
1982). 
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